Week in Review
The most important story this week was not a new valve. It was a delivery catheter that failed and killed someone. On October 16 the FDA issued an Early Alert covering four lots of the Edwards Commander M system, the catheter used to deliver the SAPIEN M3 transcatheter mitral valve, after three reports of the balloon rupturing during inflation. One patient died and one was seriously injured. The alert matters more than its narrow scope suggests, because the patients who receive this valve were chosen precisely because they cannot survive an operation, which means there is no surgical rescue when the device fails. Two days earlier, JACC published the ENCIRCLE MAC registry, which showed the same valve eliminating mitral regurgitation in 98.5% of recipients while 33.6% of them were dead or hospitalized for heart failure within a year. Elsewhere, a meta-analysis of 154,892 patients found that treating aortic stenosis plus coronary disease with catheters rather than surgery lowers death in the first months and raises it from one to six years out, and Medicare moved a step closer to paying for TAVR in aortic regurgitation, an indication with roughly 1,500 real-world patients behind it compared with a million for aortic stenosis. The quiet connective thread: procedure volumes and operator pay hit record highs this week while the evidence supporting the newest indications stayed thin.
Top Stories This Week
1. A Burst Balloon, One Death, and an FDA Early Alert on Edwards' Mitral Delivery System [NOTABLE]
The FDA's Early Alert names four Commander M lots (67718561, 67804014, 67887043, 67887044) and three reports of balloon rupture during inflation, with one death and one serious injury. The customer letter is dated October 5. Other lot numbers remain usable. The agency's stated hazards are embolism and inability to retrieve the device through the guide sheath, and its own framing is unusually direct: these patients were deemed unsuitable for surgery, so bailout carries a high risk of death.
Wire and trade coverage was immediate. Yahoo Finance led with the death, Fierce Biotech and TCTMD followed within hours. The equity market shrugged, which tells you the sell side reads this as a manufacturing problem confined to four lots rather than a design defect. That read is probably correct and also beside the point clinically.
The timing is what makes it consequential. The same week, a community hospital in Indiana announced the state's first SAPIEN M3 implant. That is the diffusion curve, and it is what turns a lot-level alert into a systems question. Neither ACC/AHA 2020 nor ESC/EACTS 2025 grants transcatheter mitral valve implantation anything above Class IIb, and the ESC confines that IIb to degenerative mitral stenosis with annular calcification at experienced centres. The phrase "experienced centres" is carrying enormous weight. Surgical mitral replacement with annular decalcification remains the guideline comparator, and for primary MR both documents keep surgical repair at Class I when a durable result is expected.
The Early Alert mechanism worked, and worked fast. The harder question for programs is what to do with a therapy whose rescue plan is that there is no rescue.
2. ENCIRCLE MAC in JACC: The Regurgitation Goes Away, the Patients Do Not Do Well [NOTABLE]
The ENCIRCLE MAC registry (Guerrero, Daniels, Whisenant, Makkar, Yadav et al., JACC, October 15) is the defining mitral paper of the week and the clinical context for story one. Prospective, single-arm, transseptal TMVR with SAPIEN M3 in symptomatic mitral valve disease caused by mitral annular calcification. Screened: 364. Implanted: 93. That 26% conversion rate is itself a headline.
One-year results: mitral regurgitation abolished in 98.5%; death or heart failure hospitalization in 33.6%; all-cause mortality 21.1%; HF hospitalization 19.4%; disabling stroke 5.1%; clinically significant LVOT obstruction 4.8%; hemolysis requiring transfusion or reintervention 9.2%; mitral reintervention 11.4%; valve thrombosis 2.3%. KCCQ, NYHA class, and 6-minute walk gains held.
Every enrolled patient had already been declined for surgical replacement and for transcatheter repair, so the comparator here is medical therapy, not an operation. Read that way, ENCIRCLE supports the ESC 2025 Class IIb and justifies nothing higher. ACC/AHA 2020 is silent on TMVI entirely. The surgical literature on mitral replacement in true MAC reports comparable mortality, which is the honest counterweight to anyone pointing at the 21.1% figure as a transcatheter indictment, but no elective surgical series would accept 5.1% disabling stroke and 9.2% hemolysis as a steady state. The accompanying JACC editorial from Safi, Khera, and Tang reads as measured rather than celebratory, which is the right register.
Technical success and clinical success are different endpoints. A device can do exactly what it was engineered to do and still leave a third of its recipients dead or in hospital within twelve months.
3. Crossing Hazards: TAVR+PCI Wins Early and Loses Late Across 154,892 Patients [NOTABLE]
Published October 16 in the Journal of Clinical Medicine, this systematic review and meta-analysis pooled 14 studies and 154,892 patients with severe AS and concomitant coronary disease, with deliberate correction of prior double-counting across overlapping registry populations. TAVR plus PCI produced lower early mortality (OR 0.60, 95% CI 0.44-0.84) and less acute kidney injury (OR 0.34). It also produced 2.18-fold more permanent pacemakers, 3.38-fold more major vascular complications, and higher mortality across 12 to 72 months (HR 1.38, 95% CI 1.28-1.49) versus SAVR plus CABG.
Caveats belong in the same breath. Nine observational studies drove the late hazard; only two randomized trials contributed; GRADE certainty was low or very low for every outcome except pacemaker implantation. Confounding by indication explains a late mortality divergence in non-randomized cohorts at least as well as biology does, and the authors explicitly decline to declare a winner.
Both guidelines already list severe CAD requiring CABG as a factor favoring SAVR. This is the strongest quantitative support that line in the factor table has received. It also sits next to the weekend's TCTMD coverage of a low-risk meta-analysis reporting that the TAVI mortality gap versus SAVR widens as years pass, which runs directly against the published five-year pooled estimate favoring TAVR (HR 0.80, 95% CI 0.66-0.97) that itself evaporates when intermediate-risk trials are excluded.
Two curves that cross are not two curves that tie. The question for the Heart Team is which side of the crossover a 68-year-old is going to live on.
4. Medicare Moves Toward Covering TAVR for Aortic Regurgitation While the Only Approved Device Recalls Catheters
CMS initiated a national coverage review for TAVR in native aortic regurgitation internally, not at a manufacturer's request, with a proposed decision expected by March 2027. ACC, SCAI, and STS filed a joint letter supporting coverage with guardrails: FDA-approved devices only, registry-based coverage with evidence development, and in-person evaluation by both an interventional cardiologist and a cardiac surgeon for every candidate. The evidence asymmetry they cite is the whole argument. Roughly one million US patients have undergone TAVR for aortic stenosis. Real-world data exist on about 1,500 treated for native AR.
Four days earlier, JenaValve issued a Class II recall on 362 Trilogy delivery catheters, covering the 23 mm (111 units), 25 mm (108 units), and 27 mm (143 units) sizes, after reports that sleeve liner separation could make deployment difficult or impossible. Trilogy is the first and only THV approved in the US specifically for severe symptomatic AR.
ESC 2025 rates TAVI for AR Class IIb and restricts it to inoperable patients with suitable anatomy. ACC/AHA 2020 does not address it at all. Surgery for symptomatic severe AR is Class I in both documents, and ESC 2025 makes valve-sparing aortic root replacement Class I in young patients. No randomized trial has compared TAVI against surgical repair or replacement in native AR. Note the policy inconsistency the societies are navigating: CMS recently eliminated coverage with evidence development for symptomatic severe AS while keeping it for asymptomatic TAVR. Reinstating it for AR is the minimum defensible position, and a delivery-system failure in the one indication with the least guideline support is a bad pairing.
5. Record Volumes, Record Pay, and a Self-Referral Question at CMS
MedAxiom's 2026 survey of more than 6,000 US physicians and advanced practice providers, reported by Cardiovascular Business, found median TAVR volume per full-time interventional cardiologist rose from 26 in 2016 to 47 in 2025. Median cardiologist compensation reached $727,712 and interventional compensation $803,934, both all-time highs. Every subspecialty hit a compensation peak. Cardiac CT and PET volumes climbed sharply too.
Running alongside it: Medscape reported that CMS rule changes are drawing self-referral questions, centered on the two-physician evaluation requirement written into the 2019 National Coverage Determination. That requirement exists for one reason: to keep the decision to implant separate from the economics of implanting. Both guidelines make Heart Team review a Class I expectation, and ESC 2025's expansion of early intervention into asymptomatic severe AS (Class IIa, LOE A, on EARLY TAVR, RECOVERY, AVATAR, and EVoLVeD) makes gatekeeping more consequential, not less. The eligible population grew. The check on who decides may be shrinking.
One more data point in the same direction. CJC Open published Canadian national trends for 2012 to 2024: AS hospitalizations rose from 259.8 to 362.4 per million, SAVR fell from 104.4 to 66.5 per million, and TAVI climbed from 19.0 to 136.9 per million. The steepest crossover was in patients aged 60 to 79, which is exactly the band where ACC/AHA 2020 calls for shared decision-making (65 to 80), where ESC 2025 prefers SAVR below 70 at low surgical risk, and where the ESC itself concedes randomized representation is poorest.
Aortic Valve (TAVR/TAVI)
Coronary complexity. The PRO-TAVI SYNTAX substudy (JACC: Cardiovascular Interventions, October 13) stratified 466 randomized patients with significant CAD by SYNTAX score. The primary composite did not differ by stratum, and PCI deferral reduced bleeding in every stratum. Above SYNTAX 17, deferral produced death, MI, or stroke in 30.9% versus 14.8% with pre-TAVR PCI (adjusted HR 2.43, 95% CI 1.04-5.64, P = 0.04). Post hoc, one quartile, a confidence interval touching 1.04. Treat it as directional. An accompanying editorial and a perspective piece both frame the open question as which patients benefit rather than whether the strategy works on average. Supporting context from the same issue: in an NCDR CathPCI analysis of 3,956,840 PCIs, severe AS was an independent predictor of intraprocedural cardiac arrest, and 40.5% of those patients died in hospital. Surgical counterpoint: both guidelines route severe CAD requiring CABG to the operating room, and combined AVR plus CABG has never had to litigate whether to revascularize complete anatomy.
Platform choice is not neutral. A nine-center retrospective in the Annals of Thoracic Surgery covering 3,652 TAVRs from 2021 to 2024, propensity matched to 680 per arm, found self-expanding valves carried higher index-hospitalization ischemic stroke, higher pacemaker need, and higher rates of both mild and moderate paravalvular leak at follow-up, with no survival difference. Center-level pacemaker rates fell sharply at high-volume centers, which is a quality finding as much as a device finding. Paired with it, PROLONG-TAVR (Catheterization and Cardiovascular Interventions, October 15) pooled 242 observational studies and 181,187 patients: SAPIEN 3 ranked lowest for moderate-to-severe PVL (1.04%, 95% CI 0.69-1.55) and stroke (1.87%, 95% CI 1.64-2.14); ACURATE neo2 ranked lowest for pacemaker (7.7%, 95% CI 5.82-10.11). The authors abandoned their planned long-term analysis because durability reporting across the literature was too sparse and inconsistent to pool. That last sentence is the one that matters. ACC/AHA 2020 built its TAVI recommendations on roughly five years of data. ESC 2025 asserts comparable structural valve deterioration against SAVR out to ten years. A 242-study synthesis that cannot pool long-term outcomes is a problem for the second claim.
Device hemodynamics without a survival signal. An updated meta-analysis in Acta Cardiologica (5 studies, 2,771 patients) found Myval lowered mean gradient by 2.37 mm Hg and raised effective orifice area by 0.26 cm² versus SAPIEN 3, sustained at one year, with flat 30-day mortality (RR 1.05) and one-year mortality (RR 0.93). Thin pool, mostly registries. In small annuli, Sá and Kilic argued in the American Journal of Cardiology that the observational signal favoring self-expanding valves has not survived replication. SAVR with root enlargement remains the ESC-favored route when patient-prosthesis mismatch dominates the decision.
Leaflet thrombosis and mechanism. A two-center study of 311 patients imaged by 4D-CT within six months of TAVR found hypoattenuated leaflet thickening in 29.3%, reduced leaflet motion in 14.5%, and an adjusted OR of 2.999 for subclinical leaflet thrombosis with skirted self-expanding prostheses (p = 0.015). Retrospective, two centers, no surgical comparator. Two studies are now chasing the mechanism: POPular PET TAVI will image 180 patients at five years with 4D-CT plus ¹⁸F-sodium fluoride PET (159 enrolled as of September 2026, completion expected December 2026), and SYMMETRY will randomize double-TAP post-dilatation in 422 patients. If the skirt signal holds, "comparable SVD" becomes a platform-specific claim, not a class claim.
Pacing. A Spanish multicenter registry of 466 propensity-matched pairs found conduction system pacing after TAVR produced cardiovascular death or HF hospitalization in 9.7% versus 17.6% with right ventricular pacing (HR 0.57, 95% CI 0.39-0.83), with HF admissions driving all of it and no mortality difference. The editorial is titled "Promise Meets Evidence," which is exactly right for a retrospective 43% relative reduction. Separately, leadless pacemakers matched transvenous devices for implant success and survival across 10,809 patients, with shorter stay and fewer HF admissions in sensitivity analysis only. Surgical counterpoint: SAVR is not pacemaker-free. Contemporary series report new third-degree AV block near 2.5% in tricuspid AS and 6.5% in bicuspid, and new LBBB after SAVR carries its own mortality hazard (HR 1.60).
Technique and physiology. A single-center series (N = 84) reported that prolonged 8-second balloon inflation achieved near-complete SAPIEN 3 Ultra RESILIA expansion with a 6% pacemaker rate and no moderate PVL, compared descriptively against published series rather than randomized. A cusp-overlap versus three-cusp comparison (113 patients, 49 matched pairs) failed to show a pacemaker reduction at roughly 19% post hoc power, which is inconclusive rather than negative. Invasive pacing studies in 46 patients showed force-frequency and relaxation-frequency reserve recover immediately after TAVI, evidence that pressure-overload dysfunction is load-dependent and reversible.
Valve-in-valve and complex anatomy. Among 113 patients undergoing ViV-TAVI inside internally stented Mitroflow or Trifecta surgical valves, 37 matched pairs showed equivalent 30-day outcomes and no difference in the 2-year composite, but supra-annular self-expanding valves delivered a markedly lower one-year mean gradient than balloon-expandable (11.7 vs 22.7 mm Hg, P < 0.001). A 22.7 mm Hg mean gradient one year after ViV is not an acceptable result in a patient with a decade or more ahead, and it is an argument for explant with root enlargement in the right candidate. Two surgical commentaries published the same week addressed exactly those operations: the small aortic annulus in an era of rising TAVR explant and the Commando procedure for invasive endocarditis of a transcatheter valve. THV explant mortality runs 12% to 17%. Technical reports this week included wire-anchored BA-BASILICA in type-0 bicuspid AS with cardiogenic shock, rescue TAVR after a failed Ozaki procedure, and four Navitor implants into protruding LVOT calcific nodules. All n ≤ 4. A complex-anatomy framework paper restated NOTION-2's three-year composite in younger bicuspid patients: 20.4% after TAVI versus 7.8% after SAVR (HR 2.9, 95% CI 0.9-9.0). Both guidelines keep bicuspid TAVI at Class IIb.
Aortic regurgitation devices. A 13-patient single-center series of the ScienCrown short-frame, fully recapturable self-expanding valve in pure native AR reported 100% technical success, 92.3% early safety, 7.7% pacemaker, and no moderate or severe residual AR at 30 days. Thirteen patients, one center, 30 days. Nothing here moves the Class IIb.
Prediction tools. A systematic review of machine learning for post-TAVR mortality pooled an AUC of 0.791 with a 0.480-0.940 prediction interval and I² of 91.5%; external validation underperformed internal (0.754 vs 0.814); high-risk-of-bias studies reported systematically higher discrimination (0.895 vs 0.747, p for interaction 0.0009); calibration appeared in 23 of 67 reports and decision-curve analysis in 10. A separate scoping review of 11 studies and 101,030 patients found AUROC ranging 0.66 to 0.97. None of these belongs in a Heart Team meeting yet. A six-patient finite-element study separated LBBB from no-LBBB by strain in the left bundle region, with self-expanding devices generating higher mean strain. Proof of concept. A Japanese multicenter score using BMI, peak velocity, and LV end-diastolic diameter stratified LVEF normalization after TAVI from 15% to 71% in 177 retrospectively derived patients. Also this week: a narrative review on prevention-first lifetime planning after TAVI, a review positioning von Willebrand factor assays as investigational adjuncts for discordant prosthetic valve imaging, a review of divergent post-TAVR anticoagulation guidance across ESC/EACTS 2025, ACC/AHA 2020, and NICE (no trial has enrolled new-onset post-procedural AF), and a Journal of Thoracic Disease editorial on seven-year PARTNER 3 that lands on reassurance plus residual uncertainty rather than resolution. Real-world transcarotid Evolut registry data also appeared in the Annals, reinforcing transcarotid as the dominant US alternate access route. A finite-element and fatigue study designed a balloon-expandable stent for Chinese aortic root anatomy, surviving 4 × 10⁸ accelerated cycles without fracture. Bench only.
Mitral Valve (Repair & Replacement)
Everything in mitral this week orbits the Commander M alert and ENCIRCLE, both covered above. The rest of the field filled in around them.
Off-label improvisation. A UK multicentre series in Heart describes transcatheter mitral valve replacement performed with TAVI implants in the mitral position. No abstract is posted, so sample size, MAC burden, LVOT obstruction rate, and mortality are unknown until full text. Hypothesis-generating at best. Surgical counterpoint: ESC 2025 caps TMVI at Class IIb for degenerative MS with MAC at experienced centres; surgical mitral replacement with annular debridement remains the comparator, and repair is Class I whenever durable.
The on-site surgery question. A comparative registry in Catheterization and Cardiovascular Interventions compared M-TEER at two centers sharing the same interventional operator team, one with on-site cardiac surgery and one without. Device success was 81.0